Clinical trial

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

NCT00340834

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Fingolimod 1.25 mg Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Fingolimod 0.5 mg Normalized identity: fingolimod 0.5 MGView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Interferon β-1a 30 µg Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-05-01

PhasePHASE3

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

Fingolimod 1.25 mgDRUG

Fingolimod 0.5 mgDRUG · verified · RxNorm: fingolimod 0.5 MG

Interferon β-1a 30 µgDRUG

Sponsors & collaborators

Novartislead sponsor

Mapped research locations

CairoEgypt4 AthensGreece3 TampaFlorida, United States2 BerlinGermany2 MontrealQuebec, Canada2 MilanItaly2 VancouverBritish Columbia, Canada2 ViennaAustria2 MünchenGermany2 Rio de JaneiroBrazil2 UlmGermany2 RosarioSanta Fe Province, Argentina2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00340834 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.